ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This phase II trials studies the side effects and how well ESK981 works in treating patients
with castration-resistant prostate cancer that has spread to other places in the body. ESK981
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.